Daily Chart: COVID-19 vaccines by phase and modality

Among the 157 COVID-19 vaccines in development, at least 18 have reached the clinic.

Sichuan Clover Biopharmaceuticals Inc. is the latest company to enter the clinic with a vaccine, announcing Friday that it had begun dosing the first volunteers in a Phase I trial of its COVID-19 candidate.

Protein-based vaccines, which include full-length viral proteins, peptide antigens and virus-like particles, make up the most common group.

Each vaccine modality comes with a different set of pros and cons and varying levels and durations of immunity (see “Guide to Preclinical Vaccine Modalities” and “Guide to Clinical Vaccine Modalities”).

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers